Founder Fubon CSI Medicine and Medical Device Innovation ETF

159929

588130

588250

159859

516820

520880

159615

560600

159849

159837

510660

589720

512290

516500

159892

SBP GROUPannounced preclinical data for its innovative drug TQF6422 at the 2026 European Congress on Obesity. TQF6422, a fully human monoclonal antibody targeting ActRII A/B, promotes muscle growth and fat reduction. Its in vitro activity exceeds comparable products by over 10 times. In combination with semaglutide, TQF6422 showed significant synergistic effects, increasing fat reduction by 1.5 to 2 times in an obese monkey model, with fat loss comprising 93% of total weight loss.

AASTOCKS News

China Universal 800 Health Care ETF

SPDR S&P Biotech

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Ark Genomic Revolution ETF

Penghua SSE STAR Biology and Medicine ETF

Proshares UltraShort Nasdaq Biotech

Tianhong CNI BIOMEDICINE ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

ALPS Medical Breakthrough

China Southern Hang Seng Biotech ETF(QDII)

Direxion S&P Biotech Bull 3X

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Guotai SSE STAR Brand Name Drug ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

SBP GROUP

SBP GROUP  Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

159883

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

iShares US Medical Devices

China Merchants CSI All Share Medical Apparatus and Instruments ETF

iShares US Pharma

ChinaAMC CSI All Share Health Care Devices ETF

Health Care Select Sector SPDR

Novo Nordisk A/S (B Shares) ADRhedged

SPDR S&P Health Equip

iShares Global Healthcare

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Tip Ranks

Bosera Hang Seng Health Care ETF(QDII)

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

HBM Holdings Ltd. announced that its independent non-executive director, Dr. Xiaoping Ye, is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations. The company stated that Dr. Ye does not engage in daily management and will cooperate with regulators. HBM's operations are reported to be normal, with no expected impact from the probe. Shareholders are advised to exercise caution during the inquiry. The latest analyst rating for HBM stock is a Buy, with a price target of HK$17.00.

HBM HOLDINGS-B

Tigermed

TIGERMED

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

A new clinical study published in Nature Communications highlights the effects of Efsubaglutide Alfa, a GLP-1 receptor agonist, on glycaemic control and β-cell function in adults with type 2 diabetes inadequately controlled on metformin. The SUPER 2 trial demonstrated significant improvements in HbA1c and other glycaemic measures, with a safety profile consistent with the GLP-1 class. The findings suggest that Efsubaglutide Alfa may also improve β-cell function, indicating potential long-term benefits beyond glycaemic control. Innogen Pharmaceuticals led the study, emphasizing the importance of mechanistic insights in developing therapies for metabolic diseases.

prnewswire

Penghua CSI HK Connect Health Care Composite ETF

VG Health

BlackRock, Inc.

INNOGEN-B

23:47 ETNew Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

StockTitan

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

300347

Shanghai-based Immunocan has successfully closed a RMB250 million Series A funding round, led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing investors like Kingray Capital and TigerYeah Capital. The funds will be utilized to enhance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, develop an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan specializes in antibody discovery using gene-editing technologies and collaborates with various pharmaceutical companies globally.

TechNode

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Antibody discovery platform Immunocan closes RMB250 million Series A

Innovent Biologics, Inc. will present clinical and preclinical results of mazdutide and its next-generation obesity and metabolic pipeline at the 2026 ADA Scientific Sessions in New Orleans from June 5-8, 2026. Key presentations include studies on mazdutide's efficacy in adults and adolescents with obesity and type 2 diabetes, highlighting its profile as a GCG/GLP-1 dual receptor agonist. The pipeline also features innovative oral GLP-1 receptor agonists and an amylin analog aimed at addressing obesity-related challenges. This event marks a significant step for Innovent in establishing leadership in obesity and metabolic disease treatment.

Unusual Whales

Guotai CSI Hugangshen Innovative Drugs Industry ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

INNOVENT BIO

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

600276

01276

Hengrui Pharma

Bristol Myers Squibb

HENGRUI PHARMA

Direxion S&P Biotech Bear 3X

ProShares Ultra Health Care ETF

Direxion Pharma & Medical Bull 3X

Bristol-Myers Squibb Company

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

Coloplast A/S reported a Q2 loss of 971 million Danish kroner, down from a profit of 912 million kroner last year, primarily due to a 3.03 billion kroner impairment loss related to Kerecis. Despite this, revenues rose 2% to 7.08 billion kroner, with organic growth of 6%. The company reaffirmed its FY26 outlook, projecting revenue growth of 3% and adjusted EBIT growth of around 5%. A half-year interim dividend of 5.00 kroner per share will be paid.

rttnews

Coloplast A/S Class B

Coloplast Slips To Loss In Q2 On Hefty Charge, Revenues Rise; Confirms FY26 Outlook

Founder Fubon CSI Medicine and Medical Device Innovation ETF(560600.SH)

SBP GROUP Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

23:47 ETNew Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function